BTIG Starts United Therapeutics Corp. (UTHR) at Neutral

BTIG initiated coverage on United Therapeutics Corp. (NASDAQ: UTHR) with a Neutral rating. Analyst Hartaj Singh views risk/reward as balanced.

"A late-2017 patent cliff for 3 out of 4 of its top products that could reduce 2018 adjusted EPS to 2013 levels (~$6-7/share) is offset by the blue sky potential for Orenitram, currently a $500m peak product in our model, though it could achieve $1-2B in peak sales if the Phase 3 FREEDOM-EV trial is positive," said Singh.

For an analyst ratings summary and ratings history on United Therapeutics Corp. click here. For more ratings news on United Therapeutics Corp. click here.

Shares of United Therapeutics Corp. closed at $127.73 yesterday.

You May Also Be Interested In

• Kepler Cheuvreux Upgrades Entain PLC (ENT:LN) (GMVHF) to Buy
• Callaway Golf (CALY) PT Raised to $20 at Truist Securities
• Canaccord Starts Aclaris Therapeutis (ACRS) at Buy